Literature DB >> 6613867

Hemodynamic effects of felodipine at rest and during exercise in exertional angina pectoris.

J M Detry, P M De Coster, J Renkin.   

Abstract

To examine the antianginal effects of felodipine, a new calcium antagonist, 8 patients with coronary artery disease and exertional angina pectoris were studied. Hemodynamic measurements were made at rest, during submaximal exercise and during angina-limited exercise before and 30 minutes after oral administration of 0.1 mg/kg of felodipine. Angina pectoris was always prevented after the drug was given and the exercise intensity was increased until recurrence of angina (5 patients) or exhaustion (3 patients). Hemodynamic data were also recorded at this higher exercise capacity. At rest and during submaximal exercise, felodipine increased heart rate and decreased arterial blood pressure and systemic vascular resistance. The prevention of angina pectoris was accompanied by lower mean pulmonary capillary wedge pressure, systemic vascular resistance and ST-segment depression; the pressure-rate product was unchanged. The 20% greater exercise capacity after felodipine was attended by a 20% increase in maximal cardiac output, a 17% increase in maximal heart rate and a 13% increase in maximal pressure-rate product; the maximal arterial blood pressure and ST-segment abnormalities were unchanged and the systemic vascular resistance was lower. The relation between ST-segment depression and the pressure-rate product during exercise was favorably influenced by felodipine. Thus, felodipine is an active antianginal drug; its major mechanism of action is to lower the systemic vascular resistance. The data also suggest that it improves coronary blood flow during exercise.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6613867     DOI: 10.1016/0002-9149(83)90006-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension.

Authors:  C Porcellati; P Verdecchia; C Gatteschi; G Benemio; M Guerrieri; F Boldrini; G Pollavini
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  The effects of felodipine in angina pectoris.

Authors:  A R Lorimer; P MacFarlane; S Pringle; M P Barbour; Y Fox; T D Lawrie
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Acute haemodynamic effects of felodipine in congestive heart failure.

Authors:  H Emanuelsson; A Hjalmarson; S Holmberg; F Waagstein
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Effects of nicardipine on coronary blood flow, left ventricular inotropic state and myocardial metabolism in patients with angina pectoris.

Authors:  M F Rousseau; M F Vincent; P Cheron; G van den Berghe; A A Charlier; H Pouleur
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 5.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

6.  Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina.

Authors:  A Kuhn; J Carlsson; S Miketic; U Tebbe
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

7.  Hemodynamic effects of felodipine in congestive heart failure.

Authors:  G Binetti; S Pancaldi; N Giovanelli; S Negroni; R M Ferretti; A Branzi; S Specchia; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

8.  The effects of treatment with felodipine as a single agent in coronary artery disease.

Authors:  M J Metcalfe; N S Chan-Wah-Hak; K Jennings
Journal:  Br Heart J       Date:  1989-03

9.  Felodipine in severe chronic congestive heart failure: acute effects on central hemodynamics and regional blood flow distribution.

Authors:  G Binetti; I Rubino; E Varani; R Spadoni; R M Ferretti; V Cervi; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.